Clinical Trials Logo

Colitis, Ulcerative clinical trials

View clinical trials related to Colitis, Ulcerative.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06353828 Active, not recruiting - Ulcerative Colitis Clinical Trials

Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

Ulcerative proctitis can lead to considerable morbidity, and the available treatment options are limited. Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic animal models of inflammation, including IBD models. Based on positive safety and initial efficacy profiles of CBD found in IBD animal and clinical studies, the main aim of this study is to evaluate the safety, tolerability and efficacy of a novel enema formulation of CBD for the treatment of active ulcerative proctitis.

NCT ID: NCT06221995 Active, not recruiting - Surgery Clinical Trials

Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery

Start date: September 25, 2023
Phase:
Study type: Observational

A prospective observational study to assess the energy needs of Ulcerative Colitis patients undergoing total proctocolectomy with ileoanal j-pouch anastomosis.

NCT ID: NCT06013696 Active, not recruiting - Ulcerative Colitis Clinical Trials

Bleach and Urine Color in UC Patients Using 5ASA

Asableach
Start date: July 16, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect on urine color by adding household bleach to fresh urine sample among pediatric UC subjects treated with 5ASA

NCT ID: NCT05896943 Active, not recruiting - Ulcerative Colitis Clinical Trials

The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab

Start date: April 1, 2022
Phase:
Study type: Observational

The investigators hope that the present study will highlight new transcriptomic prognostic markers of response to Ustekinumab with the ultimate goal of individualizing treatment and making a more targeted selection of UC patients who will benefit from this biological agent.

NCT ID: NCT05788549 Active, not recruiting - Ulcerative Colitis Clinical Trials

Assessment of the Effectiveness of Progressive Relaxation Techniques in Individuals With Ulcerative Colitis

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

Ulcerative colitis is a chronic disease that follows a course of remission and flare-ups. Especially during flare-ups, the worsening of symptoms negatively affects all aspects of the individual's life and decreases their quality of life. Individuals sometimes have difficulty accessing healthcare facilities. In addition, every hospital admission causes an additional burden on healthcare institutions and the individual, both physically and financially. Therefore, it is of great importance to support and develop self-management behaviors for individuals to control their symptoms. Progressive relaxation techniques are a relaxation method based on the principle of voluntary contraction and relaxation of muscle groups in our body. It has been reported that progressive relaxation techniques, which are applied in many chronic diseases and procedures, improve symptoms and disease parameters reported by individuals, especially pain, anxiety, and stress. When the literature in the world and Turkey is examined, no study applying progressive relaxation techniques to ulcerative colitis patients has been encountered. It is known that especially stress and anxiety affect the number and severity of flare-ups in ulcerative colitis patients. It is thought that this study will contribute to the self-management behaviors of ulcerative colitis patients in the rare diseases group for the Turkish population and fill the gap in the literature.

NCT ID: NCT05653791 Active, not recruiting - Ulcerative Colitis Clinical Trials

Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis

STEER
Start date: October 1, 2022
Phase:
Study type: Observational

Objective disease assessment in inflammatory bowel diseases at the time of treatment initiation and during follow-up has become gold standard. However, biomarkers, such as C-reactive protein and fecal calprotectin, fail to provide information on disease extent, location or complications. Repeated endoscopic assessments are performed to evaluate mucosal response to treatment, though associated costs, availability, invasiveness and patient preference are considerable limitations. Recently, intestinal ultrasound (IUS) has gained significant momentum as a non-invasive, easily accessible and low-cost alternative for objective assessment. Accordingly, the ECCO-ESGAR guideline recognizes IUS as a potential tool for the diagnosis and for the monitoring of IBD. Our study aim is to evaluate the change in intestinal ultrasound parameters (as measured by B-mode and SWE at baseline and week 4) to predict endoscopic response and remission as defined by the follow-up endoscopy and measured by the Mayo endoscopic subscore and the UCEIS during treatment with filgotinib

NCT ID: NCT05549323 Active, not recruiting - Ulcerative Colitis Clinical Trials

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Start date: November 7, 2022
Phase: Phase 1
Study type: Interventional

This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.

NCT ID: NCT05528510 Active, not recruiting - Colitis, Ulcerative Clinical Trials

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

ASTRO
Start date: September 13, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

NCT ID: NCT05384080 Active, not recruiting - Ulcerative Colitis Clinical Trials

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

VARIETY
Start date: August 8, 2022
Phase:
Study type: Observational

The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland. There is no treatment involved in this study, this is only an observational review of ongoing/initiating treatment data relating to Vedolizumab induction and maintenance treatment for IBD [including Ulcerative Colitis (UC) and Crohn's Disease (CD)].

NCT ID: NCT05291689 Active, not recruiting - Clinical trials for Inflammatory Bowel Diseases

A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

Start date: May 24, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)